IT-141 / Intezyne - LARVOL DELTA

Targeting Trop-2 in Advanced Urothelial Carcinoma - Episode 11: Novel Sequencing Strategies for Advanced Urothelial Carcinoma (OncLive) - "Neeraj Agarwal, MD:...Most of my patients will be eligible for these antibody-drug conjugates compared with my experience with cisplatin-based chemotherapy. That's definitely exciting news. I'd like to highlight 1 very important point you raised, which is that these 2 antibody-drug conjugates, enfortumab vedotin and sacituzumab govitecan, are exclusive of each other....Dr [Guru] Sonpavde...is doing a study combining the 2 antibody-drug conjugates....One of the studies we included was by Dr [Matthew] Galsky. The findings were quite surprising in that only 48% patients received first-line chemotherapy or systemic therapy....Petros Grivas, MD, PhD: It's very exciting to see the trend. Neeraj, I agree with you. We should do this study again a few years from now and see how things evolve. I share the hope with you that we're going to keep increasing the longevity and the quality of life of our patients."

Video

Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer (clinicaltrials.gov) - P1; N=10; Terminated; Sponsor: Intezyne Technologies, Inc.; N=45 ➔ 10; Recruiting ➔ Terminated; Terminated by sponsor.

Clinical • Enrollment change • Monotherapy • Trial termination • Oncology • Solid Tumor

Clinical Challenges: ADCs and Triple-Negative Breast Cancer (Let Life Happen) - "'Part of the reason it works well in breast cancer patients who have been extensively pretreated is that most of these patients have not seen a topoisomerase inhibitor before, and now they are getting it at very high concentrations,' explained Tripathy. 'And the side effects of antibody drug conjugate are similar to those seen in topoisomerase inhibitors, and to a much lower degree, because there is much less of the drug floating around than if you had given it just as a naked drug.'"

Media quote

ProLynx announces phase 1b clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38) with the PARP inhibitor Rubraca (rucaparib) at the National Cancer Institute (GlobeNewswire) - "ProLynx LLC....announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the National Cancer Institute (NCI). The trial combines its long-acting PEGylated SN-38, PLX038, with the Clovis Oncology PARP inhibitor, rucaparib."

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer